Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

IMA

ImageneBio Inc

Feb 13 • 04:00PM ET

6.91

+0.06 0.88 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-8.11	Insider Own	36.29%	Shs Outstand	10.65M	Perf Week	0.00%
Market Cap	80.93M	Forward P/E	-	EPS next Y	-4.01	Insider Trans	0.38%	Shs Float	7.46M	Perf Month	1.17%
Enterprise Value	-50.69M	PEG	-	EPS next Q	-1.38	Inst Own	32.73%	Short Float	5.18%	Perf Quarter	-19.18%
Income	-46.13M	P/S	-	EPS this Y	54.52%	Inst Trans	22.63%	Short Ratio	7.20	Perf Half Y	-53.28%
Sales	0.00M	P/B	0.55	EPS next Y	27.95%	ROA	-29.23%	Short Interest	0.39M	Perf YTD	0.14%
Book/sh	12.51	P/C	0.57	EPS next 5Y	38.40%	ROE	-33.05%	52W High	19.20 -64.01%	Perf Year	-62.36%
Cash/sh	12.17	P/FCF	-	EPS past 3/5Y	-2.47% -16.81%	ROIC	-31.04%	52W Low	5.70 21.23%	Perf 3Y	-82.55%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.94% 6.36%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	45.48%	Oper. Margin	-	ATR (14)	0.40	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.24	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	48.10	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	13.24	EPS Q/Q	-18.09%	SMA20	-2.27%	Beta	0.45	Target Price	16.00
Payout	-	Debt/Eq	0.08	Sales Q/Q	-	SMA50	2.75%	Rel Volume	0.34	Prev Close	6.85
Employees	10	LT Debt/Eq	0.06	Earnings	Nov 12 BMO	SMA200	-36.12%	Avg Volume	53.69K	Price	6.91
IPO	Mar 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-104.30% -	Trades		Volume	18,471	Change	0.88%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-25-25	Resumed	Wedbush	Underperform	$2
Oct-24-25	Initiated	Leerink Partners	Outperform	$30

Feb-10-26 07:00AM	ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer (GlobeNewswire)
Nov-12-25 07:15AM	ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team (GlobeNewswire)
Nov-06-25 08:30AM	ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences (GlobeNewswire)
Aug-05-25 09:55AM	Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade (Zacks)
Aug-01-25 04:15PM	ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:00AM	Loading…
Jul-25-25 11:00AM	Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million (GlobeNewswire)

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SLATTERY JOSEPH P	Director	Dec 24 '25	Buy	5.99	16,000	95,840	16,000	Dec 29 04:46 PM
Bonita David P	Director	Jul 25 '25	Buy	29.90	83,611	2,499,969	287,885	Jul 30 04:51 PM
Stampacchia Otello	Director	Jul 25 '25	Buy	29.90	267,556	7,999,924	454,982	Jul 30 04:47 PM

Open in Screener

CVRX

CVRx Inc

Feb 13 • 04:00PM ET

4.95

-0.74 -13.01 %

Healthcare • Medical Devices • USA • NASD

Peers: MDT BSX ABT EW SYK ISRG ZBH TFX HOLX ALGN

| Held by: VTI IWM VXF IWO VTWO IWC VTWG DFAS RSSL IWV

Index	RUT	P/E	-	EPS (ttm)	-2.04	Insider Own	39.76%	Shs Outstand	26.31M	Perf Week	-24.43%
Market Cap	129.74M	Forward P/E	-	EPS next Y	-1.73	Insider Trans	-0.60%	Shs Float	15.79M	Perf Month	-18.18%
Enterprise Value	104.53M	PEG	-	EPS next Q	-0.51	Inst Own	30.80%	Short Float	10.40%	Perf Quarter	-48.00%
Income	-53.31M	P/S	2.29	EPS this Y	3.64%	Inst Trans	-3.25%	Short Ratio	6.07	Perf Half Y	-31.63%
Sales	56.65M	P/B	3.31	EPS next Y	12.00%	ROA	-44.76%	Short Interest	1.64M	Perf YTD	-30.28%
Book/sh	1.49	P/C	1.71	EPS next 5Y	6.41%	ROE	-96.59%	52W High	15.41 -67.89%	Perf Year	-65.84%
Cash/sh	2.89	P/FCF	-	EPS past 3/5Y	-0.43% -22.44%	ROIC	-59.58%	52W Low	4.30 15.14%	Perf 3Y	-71.34%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	36.11% 56.40%	Gross Margin	83.99%	Volatility	10.73% 10.71%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1.85	EPS Y/Y TTM	24.27%	Oper. Margin	-90.49%	ATR (14)	0.63	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.72	Sales Y/Y TTM	10.45%	Profit Margin	-94.10%	RSI (14)	28.21	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	7.63	EPS Q/Q	-5.64%	SMA20	-24.17%	Beta	1.31	Target Price	11.17
Payout	-	Debt/Eq	1.28	Sales Q/Q	4.45%	SMA50	-32.34%	Rel Volume	2.59	Prev Close	5.69
Employees	223	LT Debt/Eq	1.28	Earnings	Feb 12 AMC	SMA200	-35.60%	Avg Volume	270.76K	Price	4.95
IPO	Jun 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-4.88% 1.56%	Trades		Volume	701,788	Change	-13.01%

Date	Action	Analyst	Rating Change	Price Target Change
May-09-25	Downgrade	JP Morgan	Neutral → Underweight	$7
Jan-14-25	Upgrade	William Blair	Mkt Perform → Outperform
Sep-10-24	Initiated	Cantor Fitzgerald	Overweight	$14
Jul-11-24	Reiterated	Lake Street	Buy	$18 → $12
May-01-24	Resumed	Craig Hallum	Buy	$30 → $23
May-01-24	Downgrade	William Blair	Outperform → Mkt Perform
May-01-24	Downgrade	JP Morgan	Overweight → Neutral	$36 → $13
Jan-31-23	Initiated	Lake Street	Buy	$20
Jul-18-22	Initiated	Craig Hallum	Buy	$15
Jul-26-21	Initiated	William Blair	Outperform
Jul-26-21	Initiated	Piper Sandler	Overweight	$26
Jul-26-21	Initiated	Canaccord Genuity	Buy	$30

Show Previous Ratings

Feb-13-26 08:30AM	CVRx, Inc. Q4 2025 Earnings Call Summary (Moby) -13.01%
Feb-12-26 06:19PM	CVRx Q4 Earnings Call Highlights (MarketBeat) -6.41%
05:30PM	CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:28PM	CVRx: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results (GlobeNewswire)
07:35AM	Loading…
Feb-11-26 07:35AM	What To Expect From CVRx Inc (CVRX) Q4 2025 Earnings (GuruFocus.com) -9.12%
Jan-29-26 04:10PM	CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026 (GlobeNewswire)
Jan-23-26 12:33PM	CVRx Kicks Off One Of The Largest Heart Device Trials In History (Benzinga) +11.43%
Jan-22-26 04:05PM	CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population (GlobeNewswire) +8.61%
Jan-12-26 08:00AM	CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance (GlobeNewswire) -9.86%
Jan-06-26 08:30AM	CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy (GlobeNewswire)
Dec-22-25 08:30AM	CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-19-25 08:30AM	CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-06-25 12:03AM	CVRx Inc (CVRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic Expansions (GuruFocus.com)
Nov-05-25 07:10PM	CVRx (CVRX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
06:06PM	Loading…
06:06PM	CVRx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Nov-04-25 08:37AM	Earnings To Watch: CVRx Inc (CVRX) Reports Q3 2025 Result (GuruFocus.com)
08:30AM	CVRx to Present at the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Oct-22-25 04:30PM	CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025 (GlobeNewswire)
Aug-05-25 03:04AM	CVRx Inc (CVRX) Q2 2025 Earnings Call Highlights: Revenue Growth Amidst Strategic Expansion and ... (GuruFocus.com) -9.87%
Aug-04-25 05:20PM	CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:16PM	CVRx: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Second Quarter 2025 Financial and Operating Results (GlobeNewswire)
Jul-30-25 10:00AM	Steris (STE) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-29-25 08:30AM	CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Jul-28-25 10:00AM	CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-21-25 04:30PM	CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025 (GlobeNewswire)
Jul-17-25 04:58AM	CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains? (Zacks)
Jul-16-25 07:30AM	CVRx Announces Positive News on Outpatient Payment for Barostim (GlobeNewswire) +19.01%
04:30PM	Loading…
May-28-25 04:30PM	CVRx to Present at the William Blair 45th Annual Growth Stock Conference (GlobeNewswire)
May-09-25 03:40AM	CVRx Inc (CVRX) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Sales Force Realignment ... (GuruFocus.com) -38.69%
May-08-25 06:35PM	CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:27PM	CVRx: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire)
May-07-25 11:20AM	What To Expect From CVRx Inc (CVRX) Q1 2025 Earnings (GuruFocus.com)
May-06-25 10:00AM	908 Devices Inc. (MASS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
May-01-25 10:01AM	CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-24-25 04:30PM	CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025 (GlobeNewswire) +6.06%
Apr-09-25 08:45AM	CVRx Inc: Overreaction Creates Buying Opportunity (Seeking Alpha) +17.26%
Apr-07-25 04:05PM	CVRx Reports Preliminary First Quarter 2025 Financial Results (GlobeNewswire) -46.27%
Feb-12-25 02:45PM	CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim (GlobeNewswire)
Feb-11-25 09:55AM	CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Feb-07-25 09:55AM	Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know (Zacks)
Feb-05-25 02:14AM	CVRx Inc (CVRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Rising Expenses (GuruFocus.com) -7.20%
Feb-04-25 05:45PM	CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.11%
04:49PM	CVRx: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire)
Feb-03-25 07:08AM	CVRx Inc (CVRX) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Jan-21-25 04:30PM	CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025 (GlobeNewswire) -6.47%
Jan-16-25 10:00AM	CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jan-13-25 08:00AM	CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance (GlobeNewswire) +6.14%
Dec-23-24 04:30PM	CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-26-24 08:31AM	Cvrx (CVRX) Declined Due To Turbulence In The Direct Sales Team (Insider Monkey)
Nov-20-24 04:30PM	CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +9.25%
Nov-04-24 08:00AM	CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025 (GlobeNewswire) +12.31%
Oct-30-24 03:14AM	CVRx Inc (CVRX) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses (GuruFocus.com) +31.01%
Oct-29-24 05:50PM	CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:46PM	CVRx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Third Quarter 2024 Financial and Operating Results (GlobeNewswire)
Oct-28-24 09:08AM	Earnings To Watch: CVRx Inc (CVRX) Reports Q3 2024 Result (GuruFocus.com)
Oct-21-24 08:42AM	CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock? (Zacks) +8.11%
06:40AM	CVRx announces new CPT Category I codes for Barostim heart failure therapy (Medical Device Network)
Oct-19-24 02:10PM	CVRx announces new CPT Category I codes for Barostim (TipRanks)
Oct-18-24 02:08PM	CVRx announces new CPT Category I codes for Barostim (GlobeNewswire) +17.16%
Oct-15-24 04:30PM	CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024 (GlobeNewswire)
Sep-12-24 10:13AM	CVRx touts positive two-year data for heart failure neuromodulation device (Medical Device Network) -6.17%
08:00AM	CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim (GlobeNewswire)
Sep-03-24 08:30AM	CVRx Announces Appointment of Two New Board Members (GlobeNewswire) -8.22%
Aug-26-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Arhaus, Cardlytics, and CVRx and Encourages Investors to Contact the Firm (GlobeNewswire) +14.55%
Aug-05-24 07:22PM	Insider Buying Alert: President & CEO Kevin Hykes Acquires 30,000 Shares of CVRx Inc (CVRX) (GuruFocus.com) +6.97%
05:20PM	CVRx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CVRX (PR Newswire)
Aug-02-24 08:00AM	CVRx Announces Increased Inpatient Payment for Barostim Procedure (GlobeNewswire)
Jul-31-24 04:27PM	CVRx to Present at the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire) +7.89%
Jul-29-24 05:40PM	CVRx (CVRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -14.51%
04:38PM	CVRx: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Second Quarter 2024 Financial and Operating Results (GlobeNewswire)
Jul-15-24 04:30PM	CVRx to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call on July 29th, 2024 (GlobeNewswire)
Jul-12-24 11:54AM	Strength Seen in CVRx (CVRX): Can Its 19.0% Jump Turn into More Strength? (Zacks) +14.22%
Jun-25-24 06:50AM	CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer (GlobeNewswire)
Jun-06-24 05:48AM	CVRx (CVRX) Stock Jumps 33.9%: Will It Continue to Soar? (Zacks) +8.40%
May-22-24 08:30AM	CVRx to Present at the William Blair 44th Annual Growth Stock Conference (GlobeNewswire)
May-16-24 07:30AM	CVRx Announces Key Senior Leadership Team Hires (GlobeNewswire)
May-01-24 10:45AM	CVRx, Inc. (NASDAQ:CVRX) Q1 2024 Earnings Call Transcript (Insider Monkey) -34.75%
08:39AM	Why Is CVRx (CVRX) Stock Down 32% Today? (InvestorPlace)
07:42AM	Q1 2024 CVRx Inc Earnings Call (Thomson Reuters StreetEvents)
07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Apr-30-24 08:56PM	CVRX Stock Earnings: CVRx Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:44PM	CVRx Inc (CVRX) Reports Q1 2024 Results: Revenue Growth Amid Challenges (GuruFocus.com)
04:34PM	CVRx: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports First Quarter 2024 Financial and Operating Results (GlobeNewswire)
Apr-19-24 11:14AM	CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits (Zacks)
Apr-16-24 04:30PM	CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024 (GlobeNewswire)
Apr-15-24 07:30AM	CVRx announces availability of additional data supporting long-term benefits of Barostim (GlobeNewswire)
Jan-31-24 08:00AM	CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer (GlobeNewswire)
Jan-27-24 11:10AM	CVRx, Inc. (NASDAQ:CVRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Jan-26-24 07:14AM	Q4 2023 CVRx Inc Earnings Call (Thomson Reuters StreetEvents) -6.75%
Jan-25-24 05:45PM	CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.72%
04:50PM	CVRx: Q4 Earnings Snapshot (Associated Press Finance)
04:39PM	CVRx Inc (CVRX) Reports Substantial Revenue Growth in 2023 (GuruFocus.com)

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JOHNSON & JOHNSON	10% Owner	Nov 26 '25	Sale	10.03	6,337	63,560	4,040,861	Dec 01 04:07 PM
JOHNSON & JOHNSON	10% Owner	Nov 24 '25	Sale	10.06	2,200	22,132	4,047,198	Nov 25 12:54 PM
JOHNSON & JOHNSON	10% Owner	Nov 21 '25	Sale	10.00	500	5,000	4,049,398	Nov 25 12:54 PM
JOHNSON & JOHNSON	10% Owner	Nov 12 '25	Sale	10.00	1,000	10,000	4,049,898	Nov 14 03:07 PM
JOHNSON & JOHNSON	10% Owner	Nov 06 '25	Sale	10.21	52,332	534,310	4,051,098	Nov 10 03:28 PM
JOHNSON & JOHNSON	10% Owner	Nov 07 '25	Sale	10.00	200	2,000	4,050,898	Nov 10 03:28 PM
Nielsen Kirk G.	Director	May 15 '25	Buy	5.45	10,966	59,795	1,910,134	May 19 06:46 PM
Nielsen Kirk G.	Director	May 13 '25	Buy	5.29	101,413	536,313	1,837,968	May 14 05:27 PM
Nielsen Kirk G.	Director	May 14 '25	Buy	5.23	61,200	320,364	1,899,168	May 14 05:27 PM
Nielsen Kirk G.	Director	May 12 '25	Buy	4.79	25,200	120,670	1,736,555	May 14 05:27 PM
Jain Mudit K.	Director	May 12 '25	Buy	4.66	1,500	6,986	4,900	May 13 07:12 PM
Jain Mudit K.	Director	May 13 '25	Buy	5.26	150	789	5,050	May 13 07:12 PM
Hykes Kevin	PRES & CEO	May 12 '25	Buy	4.84	5,000	24,200	133,000	May 12 07:07 PM

IMA

ImageneBio Inc

CVRX

CVRx Inc

Upgrade your FINVIZ experience